• Vaccine Ontology ID: VO_0004200
• Type: Subunit vaccine
• Status: Research
• Antigen: Recombinant BipA protein
• BipA gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0000139
  • Description: Complete Freund's adjuvant on day 1, incomplete Freund's adjuvant on day 35 (Santi et al., 2009).
• Adjuvant:
  • VO ID: VO_0000142
  • Description: Complete Freund's adjuvant on day 1, incomplete Freund's adjuvant on day 35 (Santi et al., 2009).
• Immunization Route: Intraperitoneal injection (i.p.)

• Vaccine Ontology ID: VO_0004050
• Type: Subunit vaccine
• Status: Research
• Antigen: Recombinant BPS
• sar5 gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0000128
  • Description: Aluminum phosphate (Adju-Phos; Axell Accurate Chemical & Scientific Corp.) (Erdogan et al., 2002).
• Immunization Route: subcutaneous injection

• Vaccine Ontology ID: VO_0004051
• Type: Subunit vaccine
• Status: Research
• Antigen: Purified Rib protein
• rib gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0000139
  • Description: 0.1 ml of complete Freund’s adjuvant.
• Immunization Route: subcutaneous injection

• Vaccine Ontology ID: VO_0004052
• Type: Subunit vaccine
• Status: Research
• Antigen: Recombinant Sip protein.
• Sip gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0001263
  • Description: 20 μg of QuilA adjuvant (Brodeur et al., 2000).
• Immunization Route: subcutaneous injection

Mouse Response

• Host Strain: CD‐1
• Vaccination Protocol: Active mouse maternal immunization.A maternal immunization/neonatal pup challenge model of GBS infection was used to verify the protective efficacy of BibA protein in mice. CD‐1 female mice (6–8 weeks old) were immunized intraperitoneally on days 1 (complete Freund’s adjuvant), 21, and 35 (incomplete Freund’s adjuvant) with either PBS or 20 μg of recombinant protein and were then bred 3 days after the last immunization (Santi et al., 2009).
• Challenge Protocol: Within 48 h of birth, pups were injected intraperitoneally with a dose of GBS strain 3050 that would be lethal to 90% of the population, corresponding to 3 x 10^4 colony‐forming units (CFU). Survival of pups was monitored for 3 days after challenge (Santi et al., 2009).
• Efficacy: Immunization of mice with recombinant BibA conferred protection to 69% of the challenged pups (Santi et al., 2009).

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Four-week-old female BALB/c (H-2d) mice were immunized with recombinant BPS protein on days 1, 3, 6, and 27 (30 μg/dose) by the subcutaneous route with aluminum phosphate as the adjuvant (Erdogan et al., 2002).
• Challenge Protocol: Groups of immunized and control animals were challenged on day 37 with an inoculum of the streptococcal strain Compton R corresponding to the 80% lethal dose (LD80; 5 × 10^8 bacteria/ml) in nonimmunized mice, and mortality was recorded daily (Erdogan et al., 2002).
• Efficacy: When the immunized animals were challenged with strain Compton R, approximately 88% of the vaccinated animals survived whereas mice in the control group were not protected (78% lethality) (Erdogan et al., 2002).

Mouse Response

• Host Strain: C3H/HeN
• Vaccination Protocol: Male C3H/HeN mice, 7 to 13 weeks old, were immunized subcutaneously with 25 μg of pure protein (Rib or bovine serum albumin [BSA]) in 0.1 ml of phosphate-buffered saline (PBS) mixed with 0.1 ml of complete Freund’s adjuvant. Four weeks later the mice were given boosters of the same amount of protein with incomplete Freund’s adjuvant (Larsson et al., 1996).
• Challenge Protocol: Two weeks after the booster, the mice were injected intraperitoneally (i.p.) with a 90% lethal dose (LD90) of log-phase bacteria, diluted in 0.5 ml of Todd-Hewitt broth. The LD90 for the different strains varied between 10^6 and 10^7 bacteria, as determined in preliminary experiments (Larsson et al., 1996).
• Efficacy: Vaccination of mice with the Rib protein protected against two strains of capsular type III and two strains of type II (Larsson et al., 1996).

Mouse Response

• Host Strain: CD-1
• Vaccination Protocol: Mice were injected s.c. three times at 3-week intervals with either 20 μg of purified recombinant Sip protein in 0.1 ml of PBS mixed with 20 μg of QuilA adjuvant (Cedarlane), 15 μg of formaldehyde-killed GBS WC with 20 μg of QuilA as positive controls, or 20 μg of QuilA in PBS as a negative control (Brodeur et al., 2000).
• Challenge Protocol: To evaluate the challenge dose required for each GBS strain, between 10^4 and 10^8 CFU/mouse was injected i.p. into groups of CD-1 female mice (Brodeur et al., 2000).
• Efficacy: Immunization with the recombinant Sip protein efficiently protected CD-1 mice against deadly challenges with six GBS strains of serotypes Ia/c, Ib, II/R, III, V, and VI (Brodeur et al., 2000).